You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus

Article metrics

Article menu

Download PDFPDF

XML
Immune cell therapies and immune cell engineering
Original research
Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus

 

Online download statistics by month:

Online download statistics by month: August 2020 to July 2025

AbstractFullPdf
Aug 202020220373
Sep 202013813873
Oct 2020949452
Nov 2020898932
Dec 202012112138
Jan 202110210228
Feb 2021737330
Mar 2021989841
Apr 2021727230
May 2021666644
Jun 2021808057
Jul 2021484852
Aug 20215959103
Sep 2021505055
Oct 2021343437
Nov 2021414131
Dec 2021323225
Jan 2022333615
Feb 2022373716
Mar 2022646526
Apr 2022666831
May 2022767826
Jun 2022657030
Jul 2022454621
Aug 2022707126
Sep 2022515134
Oct 2022535643
Nov 2022434515
Dec 2022353512
Jan 2023363615
Feb 2023666620
Mar 2023505128
Apr 202333339
May 2023575717
Jun 2023313116
Jul 2023363619
Aug 202341429
Sep 2023474716
Oct 2023434312
Nov 2023727232
Dec 2023666619
Jan 2024464723
Feb 2024515120
Mar 2024656560
Apr 2024606126
May 2024474925
Jun 2024454519
Jul 2024868716
Aug 20245251175
Sep 2024373919
Oct 2024404132
Nov 2024394017
Dec 2024717323
Jan 2025363742
Feb 2025404019
Mar 2025616128
Apr 2025595922
May 2025343429
Jun 2025232317
Jul 2025110
Total350835421920